Clinical Efficacy and Safety of Eight Traditional Chinese Medicine Combined with Entecavir in the Treatment of Chronic Hepatitis B Liver Fibrosis in Adults: A Network Meta-Analysis

Abstract EN

Background.

Traditional Chinese medicine (TCM) is used as an adjuvant drug for the treatment of chronic hepatitis B liver fibrosis and is used frequently.

We still do not know which TCM has the best curative effect as an adjuvant drug.

Therefore, we decided to use network meta-analysis to solve this problem.

Methods.

We used the RevMan software (5.3) and Stata software (13.0) to achieve this network meta-analysis (NMA).

The primary outcomes of this study were HA, LN, PCIII, and IV-C; the secondary outcomes of this study were AST, ALT, and HBV-DNA negative conversion rate, and the Cochrane risk-of-bias tool was used to assess the quality of the included studies.

For all outcomes, the scissors funnel plot, Egger test, and Begg test were used to detect publication bias, and sensitivity analysis was used to investigate the stability of the results.

And the meta-regression was used to explore the source of heterogeneity.

Results.

A total of 34 articles were included in this study.

The study involved a total of 3199 patients, of which 1578 were assigned to the control group and 1621 patients were assigned to the experimental group.

The number of men and women is roughly equal, and the average age is about 43 years old.

In addition, nine treatment strategies were involved in this study.

The combination of TCM and entecavir can significantly improve the patients’ HA, LN, PCIII, IV-C, AST, ALT, and HBV-DNA negative conversion rates.

The comprehensive evaluation results showed that FHC combined with entecavir has more advantages than other treatment strategies.

Conclusion.

For improving the HBV-DNA negative conversion rates, adding TCM to the therapeutic strategies does not seem to show absolute superiority.

Finally, FHC combined with entecavir is the best therapeutic strategy.